1. Advances in Dyslipidemia: What Have We Learned From ACC 2017

2. PCSK9 Inhibitors – Leading Up to Recent Outcomes Data

3. Intensive vs Standard Statin Therapy

4. GLAGOV Effect of PCSK9 Inhibitors on CHD Progression

5. IVUS Trials How Low Is Too Low When Lowering LDL-C?

6. Guidelines to Manage Dyslipidemia

7. SPIRE: Bococizumab CV Outcomes

8. FOURIER: Cardiovascular Outcomes With PCSK9 Inhibition

9. FOURIER Trial Design

10. FOURIER: LDL-C Reduction

11. FOURIER: CV Outcomes

12. FOURIER: Lower LDL-C Is Better

13. Clinical Implications of FOURIER

14. Safety of PCSK9 Monoclonal Antibodies

15. FOURIER: Safety

16. EBBINGHAUS Cognitive Study of Patients Enrolled in FOURIER Trial: Endpoints

17. Primary Endpoint Spatial Working Memory Strategy Index

18. Cognitive Assessments by Achieved LDL-C and Treatment

19. IMPROVE-IT Long-Term Efficacy and Safety

20. Abbreviations

21. Abbreviations (cont)